Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Severe COVID-19.

NCT04257656 is registered in ClinicalTrials.gov with Capital Medical University as lead sponsor.

NCT NCT04257656
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04257656 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Severe COVID-19.
Lead sponsor
Capital Medical University
Phase
Phase 3
Overall status
Terminated
Start date
February 6, 2020
Completion date
April 10, 2020
Enrollment
237 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, remdesivir, sars-cov-2